Shandong Boan Biotechnology
PublicShandong Boan Biotechnology is now publicly traded
The data on this page reflects Shandong Boan Biotechnology's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Dec 30, 2022
Last Round
Private Placement
Aug 14, 2025
Total Funding Raised
$337.88M
Company Overview
Shandong Boan Biotechnology is a biopharmaceutical company engaged in the development, production, and commercialization of therapeutic antibodies, focusing on oncology, metabolism, autoimmunology, and ophthalmology.
Sector
Biotech
AI Layer
Non-AI
Keywords
Shandong Boan Biotechnology Comparables
Compare Shandong Boan Biotechnology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BioRay Pharmaceutical Co., Ltd. | 81% | |
| LintonPharm | 62% | |
| 上海亲合力生物医药科技股份有限公司 | 47% |
Shandong Boan Biotechnology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Aug 14, 2025 | ||||
| Private Placement | Jun 11, 2025 | ||||
| IPO | Dec 30, 2022 | ||||
| Series B | Sep 1, 2021 | ||||
| Growth Equity | Jan 26, 2021 |
Shandong Boan Biotechnology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| YuanBio Venture Capital | Growth Equity |
| Starr Companies | Growth Equity |
| CCB International | Growth Equity |
| Harvest Great Bay Investment SP | IPO |
| Yantai Guofeng Investment Holding Group Co., Ltd. | Growth Equity |
| Advantech Capital | Growth Equity, Series B |
| BVCF | Growth Equity |
Shandong Boan Biotechnology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access